Dr. Waldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
132 S 10th St
1170 Main
Philadelphia, PA 19107Phone+1 215-955-6086Fax+1 215-955-5681- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1987 - 1990
Stanford University School of MedicineClass of 1987
Certifications & Licensure
CA State Medical License 1988 - Present
PA State Medical License 1991 - 2024
Clinical Trials
- Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer Start of enrollment: 2013 Oct 01
- Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Start of enrollment: 2019 Oct 30
- GCC Agonist Signal in the Small Intestine Start of enrollment: 2022 Nov 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults.Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard J Smeyne, Adam E Snook, Scott A Waldman> ;NPJ Parkinson's Disease. 2024 Apr 13
- 5 citationsIntestinal neuropod cell GUCY2C regulates visceral pain.Joshua R Barton, Annie K Londregan, Tyler D Alexander, Ariana A Entezari, Shely Bar-Ad, Lan Cheng, Angelo C Lepore, Adam E Snook, Manuel Covarrubias, Scott A Waldman> ;The Journal of Clinical Investigation. 2023 Feb 15
- Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients.Madison M Crutcher, Adam E Snook, Scott A Waldman> ;Expert Review of Clinical Pharmacology. 2022 Nov 1
- Join now to see all
Press Mentions
FDA Panel Says Poziotinib’s Benefits Don’t Outweigh Risks in NSCLC With HER2 Exon 20 MutationsSeptember 22nd, 2022
Climate Science Deniers Turn to Attacking Coronavirus ModelsApril 15th, 2020
Positive Phase I Results for Colorectal Cancer VaccineMay 3rd, 2019- Join now to see all
Grant Support
- Gastro Intestinal CancerNational Cancer Institute2010–2011
- Clinical Pharmacology Training ProgramNational Institute Of General Medical Sciences1997–2011
- Occult Lymph Node Metastases And Racial Disparities In Colon Cancer OutcomesNational Cancer Institute2009–2010
- Training Program In Human InvestigationNational Center For Research Resources2005–2009
- Guanylyl Cyclase C In Blood And Colorectal CancerNational Cancer Institute2003–2008
- Short-Term Training Program In Translational Cancer ReseNational Cancer Institute2003–2007
- Guanylyl Cyclase C As A Bi0marker For Colorectal CancerNational Cancer Institute2002–2006
- Training Program In Human InvestigationNational Heart, Lung, And Blood Institute2000–2004
- Core--Developmental TherapeuticsNational Cancer Institute2001–2002
- Short Term Training Program--Translational Cancer ResearNational Cancer Institute1997–2001
- Guanylyl Cyclase C In Blood And Colorectal CancerNational Cancer Institute1999–2000
- Allosteric Inhibition Of Guanylyl Cyclase By NucleotidesNational Heart, Lung, And Blood Institute1998–2000
- Vitamin D3 25-Hydroxylase Characterization &RegulationNational Institute Of General Medical Sciences1999
- Guanylyl Cyclase C As A Biomarker For Colorectal CancerNational Cancer Institute1998–1999
- Molecular Characterization Of E Coli Toxin ReceptorsNational Institute Of Diabetes And Digestive And Kidney Diseases1992
Hospital Affiliations
Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
